http://goldbamboo.com/ Phenylketonuria News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved http://goldbamboo.com/news-a212077.html BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the pivotal Phase 3 extension study of Phenoptin (sapropterin hydrochloride), an investigational oral small molecule for the treatment of patients with phenylketonuria (PKU), who have elevated phenylalanine (Phe) levels. [click link for full article] Tue, 19 Dec 2006 08:00 EST